These include (1) the study included primary, recurrent, and metastatic angiosarcoma specimens, and although multiple studies have shown stability in expression between primary and metastatic sites (25), it is not known if PD-L1 expression evolves for angiosarcoma; (2) the intratumoral heterogeneity of PD-L1 expression is not known, and, therefore, the spatial location of the sample tested may alter our findings; and (3) finally, anti-PD-1 therapy was recently approved for any tumor with mismatch repair deficiency. Here, CD274 is linked to angiosarcoma.